← Eichor
Condition: Hhv 8 Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hhv 8

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
Phase 4 · 1 location(s) · Tongji Hospital · NCT06236022Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
NA · 1 location(s) · Alpha Tau Medical LTD. · NCT03889899Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Phase N/A · 8 location(s) · AIDS Malignancy Consortium · NCT05663502Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cance
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT00006518A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05859074Trial of Ixazomib for Kaposi Sarcoma
Phase 2 · 11 location(s) · AIDS Malignancy Consortium · NCT04305691Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT03300830Natural History Study of Kaposi Sarcoma
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT06375122Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility Trial
Phase N/A · 1 location(s) · Washington University School of Medicine · NCT06751355Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
NA · 1 location(s) · Alpha Tau Medical LTD. · NCT04534127PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT04303117Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and I
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT07308886Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT04941274Agnostic Therapy in Rare Solid Tumors
Phase 2 · 8 location(s) · Instituto do Cancer do Estado de São Paulo · NCT06638931Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Ass
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06052618Propranolol for the Treatment of Kaposi Sarcoma in Adults
Phase 2 · 1 location(s) · Washington University School of Medicine · NCT06445166AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)
NA · 1 location(s) · Implenomics · NCT06004011Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT04902443Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Diseas
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05907759Precision Imaging to Evaluate Kaposi Sarcoma
NA · 2 location(s) · Washington University School of Medicine · NCT06898203Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT01419561Study of SGR-1505 in Mature B-Cell Neoplasms
Phase 1 · 36 location(s) · Schrödinger, Inc. · NCT05544019
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.